Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2022 Apr 25

PMID 35467861

Authors

Yubai Zhou

Sandip Mukherjee

Daowei Huang

Molee Chakraborty

Chunfang Gu

Guangning Zong

Michael A Stashko

Kenneth H Pearce

Stephen B Shears

Anutosh Chakraborty

Huanchen Wang

Xiaodong Wang

Affiliations

Soon will be listed here.

Abstract

Obesity and obesity-induced metabolic dysfunctions are significant risk factors for nonalcoholic fatty liver disease and cardiovascular diseases. Thus, obesity is an economic and social burden in developed countries. Blocking the synthesis of inositol pyrophosphates by inositol hexakisphosphate kinase (IP6K) has been identified as a potential therapeutic strategy for obesity and related diseases. We have developed a novel and potent IP6K inhibitor (UNC7467) (IC values: IP6K1 8.9 nM; IP6K2 4.9 nM; IP6K3 1320 nM). Inositol phosphate profiling of the HCT116 colon cancer cell line demonstrates that reduced levels of inositol pyrophosphates by 66-81%, without significantly perturbing levels of other inositol phosphates. Furthermore, intraperitoneal injection of in diet-induced obese mice improved glycemic profiles, ameliorated hepatic steatosis, and reduced weight gain without altering food intake. Thus, inhibitor can be used as an probe for IP6K-related research. Moreover, it may have therapeutic relevance in treating obesity and related diseases.

Citing Articles

Homeostatic coordination of cellular phosphate uptake and efflux requires an organelle-based receptor for the inositol pyrophosphate IP8.

Li X, Kirkpatrick R, Wang X, Tucker C, Shukla A, Jessen H Cell Rep. 2024; 43(6):114316.

PMID: 38833370 PMC: 11284862. DOI: 10.1016/j.celrep.2024.114316.

Shaping the Future of Obesity Treatment: In Silico Multi-Modeling of IP6K1 Inhibitors for Obesity and Metabolic Dysfunction.

Mondal I, Halder A, Pattanayak N, Mandal S, Cordeiro M Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399478 PMC: 10891520. DOI: 10.3390/ph17020263.

Deleting IP6K1 stabilizes neuronal sodium-potassium pumps and suppresses excitability.

Jin H, Liu A, Chin A, Fu C, Shen H, Cheng W Mol Brain. 2024; 17(1):8.

PMID: 38350944 PMC: 10863101. DOI: 10.1186/s13041-024-01080-y.

Fragment-Based Screening Identifies New Quinazolinone-Based Inositol Hexakisphosphate Kinase (IP6K) Inhibitors.

Heitmann T, Liao G, de Leon P, Ernst G, Buchler I, Wei H ACS Med Chem Lett. 2023; 14(12):1760-1766.

PMID: 38116421 PMC: 10726443. DOI: 10.1021/acsmedchemlett.3c00409.

An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor.

Aguirre T, Dornan G, Hostachy S, Neuenschwander M, Seyffarth C, Haucke V Elife. 2023; 12.

PMID: 37843983 PMC: 10578927. DOI: 10.7554/eLife.88982.

References

Wadden T, Berkowitz R, Sarwer D, Steinberg C . Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001; 161(2):218-27. DOI: 10.1001/archinte.161.2.218. View

Stevenson-Paulik J, Chiou S, Frederick J, dela Cruz J, Seeds A, Otto J . Inositol phosphate metabolomics: merging genetic perturbation with modernized radiolabeling methods. Methods. 2006; 39(2):112-21. DOI: 10.1016/j.ymeth.2006.05.012. View

Zhu Q, Ghoshal S, Tyagi R, Chakraborty A . Global IP6K1 deletion enhances temperature modulated energy expenditure which reduces carbohydrate and fat induced weight gain. Mol Metab. 2017; 6(1):73-85. PMC: 5220553. DOI: 10.1016/j.molmet.2016.11.010. View

Fujii M, York J . A role for rat inositol polyphosphate kinases rIPK2 and rIPK1 in inositol pentakisphosphate and inositol hexakisphosphate production in rat-1 cells. J Biol Chem. 2004; 280(2):1156-64. DOI: 10.1074/jbc.M412006200. View

Moritoh Y, Abe S, Akiyama H, Kobayashi A, Koyama R, Hara R . The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals. Nat Commun. 2021; 12(1):4847. PMC: 8358040. DOI: 10.1038/s41467-021-24934-8. View

Rao F, Cha J, Xu J, Xu R, Vandiver M, Tyagi R . Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2. Mol Cell. 2014; 54(1):119-132. PMC: 4011022. DOI: 10.1016/j.molcel.2014.02.020. View

Mukherjee S, Chakraborty M, Ulmasov B, McCommis K, Zhang J, Carpenter D . Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Mol Metab. 2021; 54:101364. PMC: 8609165. DOI: 10.1016/j.molmet.2021.101364. View

Wang H, Shears S . Structural features of human inositol phosphate multikinase rationalize its inositol phosphate kinase and phosphoinositide 3-kinase activities. J Biol Chem. 2017; 292(44):18192-18202. PMC: 5672042. DOI: 10.1074/jbc.M117.801845. View

Li X, Gu C, Hostachy S, Sahu S, Wittwer C, Jessen H . Control of XPR1-dependent cellular phosphate efflux by InsP is an exemplar for functionally-exclusive inositol pyrophosphate signaling. Proc Natl Acad Sci U S A. 2020; 117(7):3568-3574. PMC: 7035621. DOI: 10.1073/pnas.1908830117. View

10.

Rao F, Xu J, Fu C, Cha J, Gadalla M, Xu R . Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proc Natl Acad Sci U S A. 2015; 112(6):1773-8. PMC: 4330756. DOI: 10.1073/pnas.1424642112. View

11.

Szijgyarto Z, Garedew A, Azevedo C, Saiardi A . Influence of inositol pyrophosphates on cellular energy dynamics. Science. 2011; 334(6057):802-5. DOI: 10.1126/science.1211908. View

12.

Hou Q, Liu F, Chakraborty A, Jia Y, Prasad A, Yu H . Inhibition of IP6K1 suppresses neutrophil-mediated pulmonary damage in bacterial pneumonia. Sci Transl Med. 2018; 10(435). PMC: 6435359. DOI: 10.1126/scitranslmed.aal4045. View

13.

Puhl-Rubio A, Stashko M, Wang H, Hardy P, Tyagi V, Li B . Use of Protein Kinase-Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors. SLAS Discov. 2018; 23(9):982-988. PMC: 6148399. DOI: 10.1177/2472555218775323. View

14.

Liao G, Ye W, Heitmann T, Ernst G, DePasquale M, Xu L . Identification of Small-Molecule Inhibitors of Human Inositol Hexakisphosphate Kinases by High-Throughput Screening. ACS Pharmacol Transl Sci. 2021; 4(2):780-789. PMC: 8033760. DOI: 10.1021/acsptsci.0c00218. View

15.

Wang H, Falck J, Hall T, Shears S . Structural basis for an inositol pyrophosphate kinase surmounting phosphate crowding. Nat Chem Biol. 2011; 8(1):111-6. PMC: 3923263. DOI: 10.1038/nchembio.733. View

16.

Jadav R, Chanduri M, Sengupta S, Bhandari R . Inositol pyrophosphate synthesis by inositol hexakisphosphate kinase 1 is required for homologous recombination repair. J Biol Chem. 2012; 288(5):3312-21. PMC: 3561551. DOI: 10.1074/jbc.M112.396556. View

17.

Kim G, Lin J, Blomain E, Waldman S . Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2013; 95(1):53-66. PMC: 4054704. DOI: 10.1038/clpt.2013.204. View

18.

Ramasamy A, Laliberte F, Aktavoukian S, Lejeune D, DerSarkissian M, Cavanaugh C . Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry. J Occup Environ Med. 2019; 61(11):877-886. DOI: 10.1097/JOM.0000000000001693. View

19.

Shears S . Intimate connections: Inositol pyrophosphates at the interface of metabolic regulation and cell signaling. J Cell Physiol. 2017; 233(3):1897-1912. PMC: 5694711. DOI: 10.1002/jcp.26017. View

20.

Moritoh Y, Oka M, Yasuhara Y, Hozumi H, Iwachidow K, Fuse H . Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice. Sci Rep. 2016; 6:32072. PMC: 5006000. DOI: 10.1038/srep32072. View